Disclosure notice

Disclosure notice Dormant Properties AB, a company controlled by Tripep's Chairman of the Board, Rolf L. Nordström, acquired a total of 86,000 Tripep AB shares on 3 February 2004. After the acquisition, Dormant Properties owns 3,182,841 shares and 0 options in Tripep. The holding is equivalent to 25.5 per cent of Tripep's share capital, excluding outstanding warrants, and 21.8 per cent after full dilution of outstanding warrants. Tripep's repurchased shares and warrants held by the company have been excluded from the calculations. For more information,please contactRolf L.Nordström,tel.+44 77 76 13 74 00 Tripep is a biotech research company that develops and commercialises candidate drugs based on patented and patent-pending technologies: -research and development of alfaHGA, a potential HIV-inhibiting drug, -preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, and the RAS® technology platform. -producing vaccines against influenza, allergies and Alzheimer's Disease through associated company VLP Biotech Inc. More details on Tripep's technologies are available at its Website: www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/02/04/20040204BIT20250/wkr0002.pdf http://www.waymaker.net/bitonline/2004/02/04/20040204BIT20250/wkr0009.doc

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.